Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caelyx in Elderly Breast Cancer
NCT00604968Phase 4Terminated
- Sponsor
- Merck & Co.
- Start
- Feb 2007
- Primary completion
- Oct 2009
01
Overview
A Phase 4 trial of pegylated liposomal doxorubicin in breast cancer, sponsored by Merck & Co.. Started Feb 2007; status: terminated.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00604968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00604968.